The future of KRAS inhibitors looks promising, with ongoing research focused on overcoming current challenges. Innovations in drug design, such as covalent inhibitors and allosteric modulators, are expected to improve specificity and reduce toxicity. Additionally, understanding the mechanisms of resistance will aid in developing more effective combination therapies.
